BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HSK44459 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HSK44459\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07623486-1385@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HSK44459: Phase 1/2 readout est. (NCT07623486)
DESCRIPTION:HSK44459\, phase 1/2\, Psoriasis.\nStudy: Trial of HSK44459 Cre
 am for the Management Plaque Psoriasis\nEstimated primary completion: Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hsk44459#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07623486
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070739-1385@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HSK44459: Phase 2 readout est. (NCT07070739)
DESCRIPTION:HSK44459\, phase 2.\nStudy: A Long-term Study of HSK44459 Table
 ts in Participants With Bechet's Disease\nEstimated primary completion: Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/hsk44459#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0707073
 9
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519070-1385@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280405
DTEND;VALUE=DATE:20280406
SUMMARY:HSK44459: Phase 3 readout est. (NCT07519070)
DESCRIPTION:HSK44459\, phase 3\, Idiopathic Pulmonary Fibrosis.\nStudy: A M
 ulticenter\, Randomized\, Double-Blind\, Placebo-Controlled Phase III Stud
 y to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With
  Idiopathic Pulmonary Fibrosis\nEstimated primary completion: 5 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hsk44459#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07519070
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503587-1385@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:HSK44459: Phase 3 readout est. (NCT07503587)
DESCRIPTION:HSK44459\, phase 3.\nStudy: Evaluating the Efficacy and Safety 
 of of HSK44459 in People With Progressive Pulmonary Fibrosis\nEstimated pr
 imary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hsk44459#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07503587
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
